Literature DB >> 23749490

Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma.

Xiong-Xiong Lu1, Shu-Min Zhang, Yuan Fang, Zheng-Ting Wang, Jun-Jie Xie, Qian Zhan, Xia-Xing Deng, Hao Chen, Jia-Bin Jin, Cheng-Hong Peng, Hong-Wei Li, Bai-Yong Shen.   

Abstract

The aim of this study was to analyze the clinical significance of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) promoter methylation in pancreatic ductal adenocarcinoma (PDA). Methylation-specific polymerase chain reaction was used to examine the promoter methylation status of RECK in 60 pairs of PDA tissue samples and adjacent non-cancerous tissue samples. Statistical analyses were applied to test the associations between RECK promoter methylation status, clinicopathologic factors, and prognosis. The rate of RECK promoter methylation was significantly higher in PDA tissues than in adjacent non-cancerous tissues (P < 0.001). RECK methylation status was significantly associated with clinical stage (P = 0.017), histological differentiation (P = 0.046), and lymph node metastasis (P = 0.003), but was not associated with gender, age, and tumor location (all P > 0.05). Additionally, RECK promoter methylation is associated with malignant behavior and poor prognosis. In conclusion, determination of RECK promoter methylation status in tumor tissues may assist in the identification of patients who require aggressive postoperative intervention in order to improve prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23749490     DOI: 10.1007/s13277-013-0903-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  Low expression of RECK indicates a shorter survival for patients with invasive breast cancer.

Authors:  Yue Zhang; Shaoqiang Cheng; Guoqiang Zhang; Wenjie Ma; Yang Liu; Rui Zhao; Qingyuan Zhang; Da Pang
Journal:  Cancer Sci       Date:  2012-04-19       Impact factor: 6.716

2.  Role of RECK methylation in gastric cancer and its clinical significance.

Authors:  Yun-Yi Du; Dong-Qiu Dai; Zhi Yang
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

3.  The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.

Authors:  J Oh; R Takahashi; S Kondo; A Mizoguchi; E Adachi; R M Sasahara; S Nishimura; Y Imamura; H Kitayama; D B Alexander; C Ide; T P Horan; T Arakawa; H Yoshida; S Nishikawa; Y Itoh; M Seiki; S Itohara; C Takahashi; M Noda
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

4.  Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis.

Authors:  Yan Fei Deng; Dong Ni Zhou; Chun Sheng Ye; Liang Zeng; Ping Yin
Journal:  Ann Otol Rhinol Laryngol       Date:  2012-07       Impact factor: 1.547

Review 5.  Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.

Authors:  Angela L McCleary-Wheeler; Gwen A Lomberk; Frank U Weiss; Günter Schneider; Muller Fabbri; Tara L Poshusta; Nelson J Dusetti; Sandra Baumgart; Juan L Iovanna; Volker Ellenrieder; Raul Urrutia; Martin E Fernandez-Zapico
Journal:  Cancer Lett       Date:  2012-10-13       Impact factor: 8.679

6.  Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.

Authors:  Z Jin; Y Mori; J Yang; F Sato; T Ito; Y Cheng; B Paun; J P Hamilton; T Kan; A Olaru; S David; R Agarwal; J M Abraham; D Beer; E Montgomery; S J Meltzer
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

Review 7.  RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling.

Authors:  Makoto Noda; Junseo Oh; Rei Takahashi; Shunya Kondo; Hitoshi Kitayama; Chiaki Takahashi
Journal:  Cancer Metastasis Rev       Date:  2003 Jun-Sep       Impact factor: 9.264

8.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK.

Authors:  C Takahashi; Z Sheng; T P Horan; H Kitayama; M Maki; K Hitomi; Y Kitaura; S Takai; R M Sasahara; A Horimoto; Y Ikawa; B J Ratzkin; T Arakawa; M Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  Global levels of histone modifications predict prognosis in different cancers.

Authors:  David B Seligson; Steve Horvath; Matthew A McBrian; Vei Mah; Hong Yu; Sheila Tze; Qun Wang; David Chia; Lee Goodglick; Siavash K Kurdistani
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

10.  Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC.

Authors:  M Pesta; V Kulda; O Topolcan; J Safranek; J Vrzalova; R Cerny; L Holubec
Journal:  Anticancer Res       Date:  2009-11       Impact factor: 2.480

View more
  4 in total

1.  Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma.

Authors:  Leisheng Wang; Junbo Ge; Tian Ma; Yanpin Zheng; Shiqiao Lv; Yu Li; Shaoxian Liu
Journal:  Tumour Biol       Date:  2015-07-01

2.  Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK.

Authors:  Lin Lei; Yaping Huang; Wenrong Gong
Journal:  Mol Cell Biochem       Date:  2013-10-27       Impact factor: 3.396

3.  Identification of RECK as an evolutionarily conserved tumor suppressor gene for zebrafish malignant peripheral nerve sheath tumors.

Authors:  Rashmi Kumari; Martin R Silic; Yava L Jones-Hall; Alexandra Nin-Velez; Jer-Yen Yang; Suresh K Mittal; GuangJun Zhang
Journal:  Oncotarget       Date:  2018-05-04

Review 4.  Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis.

Authors:  Laura Casalino; Pasquale Verde
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.